(RTTNews) - argenx SE (ARGX) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved VYVDURA for adults with chronic inflammatory demyelinating polyneuropathy. VYVDURA is ...

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...

Vyvgart Hytrulo is a prescription medicine used for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). The ADHERE trial was a multicenter, randomized, ...

for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVDURA was approved for CIDP as a once weekly 30-to-90 second subcutaneous injection, which can be self-administered at ...

Dianthus Therapeutics is advancing treatments for autoimmune diseases. Read why DNTH stock is receiving Buy ratings and price ...

JMP Securities analyst Jason Butler raised the firm’s price target on Argenx (ARGX) to $696 from $606 and keeps an Outperform rating on the ...

Soleo Health, a leader and national provider of complex specialty pharmacy services, announced Jan. 7 the opening of its new ...

Kain Science passes technical evaluation for KOSDAQ special listing Kain Science moves closer to KOSDAQ listing after ...

Cantor Fitzgerald issued their FY2025 earnings estimates for Dianthus Therapeutics in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company ...

Analysts have recently evaluated KORU Medical Systems and provided 12-month price targets. The average target is $4.7, ...